Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration

References

• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–16. doi:10.1016/S2214-109X(13)70145-1
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805–2816. doi:10.1056/NEJMoa042760
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL, et al.; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–1398. doi:10.1016/j.ophtha.2012.03.053.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444. doi:10.1056/NEJMoa062655
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in neovascular age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548. doi:10.1016/j.ophtha.2012.09.006
   PubMed Web of Science ®Google Scholar
• Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292–2299. doi:10.1016/j.ophtha.2013.03.046
   PubMed Web of Science ®Google Scholar
• Maguire MG, Martin DF, Ying GS, et al.; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(8):1751–1761. doi:10.1016/j.ophtha.2016.03.045.
   PubMed Web of Science ®Google Scholar
• Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220–226. doi:10.1136/bjophthalmol-2014-305327
   PubMed Web of Science ®Google Scholar
• Rao P, Lum F, Wood K, et al. Real-world vision in age-related macular degeneration patients treated with single Anti-VEGF drug type for 1 year in the IRIS registry. Ophthalmology. 2018;125(4):522–528. doi:10.1016/j.ophtha.2017.10.010
   PubMed Web of Science ®Google Scholar
• Souied EH, Gekkiev B, Bretagne A, et al. Ranibizumab in a real-world clinical setting: 2014 interim analysis of the 5-year observational multicenter LUMINOUS study. Invest Ophthalmol Vis Sci. 2015;56:1417.
   Web of Science ®Google Scholar
• American Society of Retina Specialists (ASRS). Annual preferences and trends survey, 2018. Available from: https://www.asrs.org/content/documents/_2018-asrs-pat-survey-results-for-website-1.pdf. Accessed July 22, 2019.
   Google Scholar
• Engelbert M, Zweifel SA, Freund KB. “Treat and extend” dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina. 2009;29(10):1424–1431. doi:10.1097/IAE.0b013e3181bfbd46
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Croft DE, Brown DM, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology. 2015;122(12):2514–2522. doi:10.1016/j.ophtha.2015.08.009
   PubMed Web of Science ®Google Scholar
• Kertes PJ, Galic IJ, Greve M. Canadian treat-and-extend analysis trial with ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized canadian treat-and-extend analysis trial with ranibizumab study. Ophthalmology. 2019;126(6):841–848. doi:10.1016/j.ophtha.2019.01.013
   Google Scholar
• Silva R, Berta A, Larsen M, et al. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology. 2018;125(1):57–65. doi:10.1016/j.ophtha.2017.07.014
   PubMed Web of Science ®Google Scholar
• Berg K, Hadzalic E, Gjertsen I. Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol: two-year results. Ophthalmology. 2016;123(1):51–59. doi:10.1016/j.ophtha.2015.09.018
   PubMed Web of Science ®Google Scholar
• Borras L, Gunde T, Tietz J, et al. Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies. J Biol Chem. 2010;285(12):9054–9066. doi:10.1074/jbc.M109.072876
   PubMed Web of Science ®Google Scholar
• Gaudreault J, Gunde T, Floyd HS, et al. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53:3025.
   Google Scholar
• Tietz J, Schmid G, Konrad J, et al. Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor a for the treatment of retinal disorders. Invest Ophthalmol Vis Sci. 2015;56:1501.
   Web of Science ®Google Scholar
• Holz FG, Dugel PU, Weissgerber G, et al. Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study. Ophthalmology. 2016;123(5):1080–1089. doi:10.1016/j.ophtha.2015.12.030
   PubMed Web of Science ®Google Scholar
• Dugel PU, Jaffe GJ, Sallstig P, et al. brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124(9):1296–1304. doi:10.1016/j.ophtha.2017.03.057
   PubMed Web of Science ®Google Scholar
• Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. Epub 2019 Apr 12.
   Web of Science ®Google Scholar
• Dugel P Brolucizumab for neovascular AMD: the 2 year HAWK and HARRIER results. Presentation at the American Academy of Ophthalmology; October 27; 2018; Chicago, IL.
   Google Scholar
• Ohji M, Okada AA, Takahashi K, et al. Use of intravitreal aflibercept treat-and-extend dosing for neovascular age-related macular degeneration: 96-week ALTAIR results. Chicago IL: Presented at AAO; 2018.
   Google Scholar
• Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145(2):239–248. doi:10.1016/j.ajo.2007.10.004
   PubMed Web of Science ®Google Scholar
• Callanan D, Kunimoto D, Maturi RK, et al. Double-masked, randomized, Phase 2 evaluation of abicipar pegol (an Anti-VEGF DARPin therapeutic) in neovascular age-related macular degeneration. J Ocul Pharmacol Ther. 2018;34:700–709. doi:10.1089/jop.2018.0062
   PubMed Web of Science ®Google Scholar
• Fewer doses of abicipar yield similar efficacy as ranibizumab for wet AMD. [ cited May 14, 2019]. https://www.healio.com/ophthalmology/retina-vitreous/news/online/%7b14e2869b-0981-415c-b8d9-485d05185d92%7d/fewer-doses-of-abicipar-yield-similar-efficacy-as-ranibizumab-for-neovascular-amd. Accessed July 12, 2019.
   Google Scholar
• Allergan and molecular partners announce topline safety results from MAPLE study of abicipar pegol. [ cited May 14, 2019]. https://www.molecularpartners.com/allergan-and-molecular-partners-announce-topline-safety-results-from-maple-study-of-abicipar-pegol/. Accessed July 12, 2019.
   Google Scholar
• Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized Phase 2 ladder clinical trial. Ophthalmology. 2019. doi:10.1016/j.ophtha.2019.03.036
   Web of Science ®Google Scholar
• Rakoczy EP, Magno AL, Lai CM, et al. Three-year follow-up of Phase 1 and 2a rAAV.sFLT-1 subretinal gene therapy trials for exudative age related macular degeneration. Am J Ophthalmol. 2019;204:113–123. doi:10.1016/j.ajo.2019.03.006
   PubMed Web of Science ®Google Scholar
• Update for RGX-314 for the treatment of wet AMD at the American academy of ophthalmology 2018 meeting. [ cited May 14, 2019]. http://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-additional-positive-interim-phase-i-trial. Accessed July 12, 2019.
   Google Scholar
• Adverum biotechnologies announces IND active for ADVM-022, a novel gene therapy to treat wet age-related macular degeneration. cited May 14, 2019. http://investors.adverum.com/news-releases/news-release-details/adverum-biotechnologies-announces-ind-active-advm-022-novel-gene. Accessed July 12, 2019.
   Google Scholar